MARQIBO KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MARQIBO KIT (MARQIBO KIT).

How it works

Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.

What the body does with it

Metabolism	Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Excretion	Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Half-life	Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Protein binding	Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
Volume of Distribution	Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
Bioavailability	Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
Onset of Action	Onset of clinical effect (antitumor activity) is typically observed within 1-2 weeks of initiating therapy, corresponding to the time required for vincristine to reach therapeutic concentrations in tumor tissues.
Duration of Action	Duration of clinical effect after a single dose is approximately 2-3 weeks, allowing for every-2-week dosing schedule. The prolonged duration is attributed to the sustained release from liposomes and the long half-life.

Classification & Brands

Dosing & administration

2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.

Dosage form	INJECTABLE, LIPOSOMAL
Renal impairment	No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 mL/min due to potential for increased exposure.
Liver impairment	Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
Pediatric use	Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
Geriatric use	No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MARQIBO KIT (MARQIBO KIT).

Breastfeeding	No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
Teratogenic Risk	Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

MARQIBO is for intravenous use only. Fatal if given intrathecally. Use only with a medical provider experienced in the administration of chemotherapeutic agents. Contains vincristine sulfate, a vesicant. Ensure proper administration technique.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.

Clinical Precautions

Precautions

Extensive extravasation precautions required; neurotoxicity (peripheral neuropathy, autonomic neuropathy); hematologic toxicity (myelosuppression); gastrointestinal toxicity (constipation, ileus); hepatic impairment; monitor serum uric acid levels; embryo-fetal toxicity.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MARQIBO KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MARQIBO KIT (MARQIBO KIT).

How it works

Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.

What the body does with it

Metabolism	Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Excretion	Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Half-life	Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Protein binding	Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
Volume of Distribution	Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
Bioavailability	Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
Onset of Action	Onset of clinical effect (antitumor activity) is typically observed within 1-2 weeks of initiating therapy, corresponding to the time required for vincristine to reach therapeutic concentrations in tumor tissues.
Duration of Action	Duration of clinical effect after a single dose is approximately 2-3 weeks, allowing for every-2-week dosing schedule. The prolonged duration is attributed to the sustained release from liposomes and the long half-life.

Classification & Brands

Dosing & administration

2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.

Dosage form	INJECTABLE, LIPOSOMAL
Renal impairment	No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 mL/min due to potential for increased exposure.
Liver impairment	Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
Pediatric use	Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
Geriatric use	No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MARQIBO KIT (MARQIBO KIT).

Breastfeeding	No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
Teratogenic Risk	Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.